Drug Profile
Research programme: glucokinase activators - Poxel
Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Poxel
- Class Antihyperglycaemics
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Type-2-diabetes-mellitus in France
- 21 Oct 2016 Glucokinase activators are still in Early research phase for Type-2 diabetes mellitus in France (Poxel pipeline)
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in France